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Abstract Fatigue is a common but often overlooked
symptomafterstroke.Thisstudyinvestigatedwhetherstroke
type, infarct volume, and laterality, as well as the levels of
various cytokines and other blood components in the acute
phaseofacuteischemicstroke(AIS),canpredictthelevelof
fatigue at 6, 12, and 18 months after its onset. In 45 patients
with acute stroke, serum levels of C-reactive protein,
hemoglobin, glucose, and 13 cytokines were measured
within 72 h of stroke onset. The cytokine measurements
were performed using BioPlex XMap technology (Lumin-
ex). The acute serum levels of interleukin (IL)-1b and glu-
cose werepositively correlated with the score on the Fatigue
Severity Scale (FSS) at 6 months after the stroke (r = 0.37,
p = 0.015, and r = 0.37, p=0.017, respectively). The
acute serum levels of IL-ra and IL-9 were negatively
correlated with FSS score at 12 months after the stroke
(r=-0.38, p=0.013, and r=-0.36, p=0.019, respec-
tively). The FSS score at 12 months after stroke was sig-
niﬁcantly lower in patients with radiologically conﬁrmed
infarction than in those without such conﬁrmation (p=
0.048). The FSS score at 18 months was not correlated with
any of the measured variables. High acute serum levels of
glucose and IL-1b, and low IL1-ra and IL-9 may predict
fatigue after AIS, indicating that the development of post-
stroke fatigue can be accounted for by the proinﬂammatory
responseassociatedwithAIS.Thesenovelﬁndingssupporta
new cytokine theory of fatigue after stroke. However, more
research is needed to validate the results of this study.
Keywords Acute ischemic stroke  Inﬂammation 
Cytokines  Proinﬂammatory  Anti-inﬂammatory
Introduction
Stroke is the second most common cause of death and is a
major cause of disability worldwide [1]. Many stroke sur-
vivors cope with chronic health problems that require a
long-term process of recovery and rehabilitation. Fatigue is
a common but often overlooked symptom after stroke [2].
Indeed, there are several reports of fatigue being a common
difﬁculty after stroke, with a frequency ranging from 29 to
68% (compared to 20% in control groups) [3]. This sig-
niﬁcant variability in the prevalence of poststroke fatigue
(PSF) is probably related to varying deﬁnitions and meth-
ods of assessing fatigue, as well as sampling of different
populations [4].
PSF represents a complex interaction of biological,
psychosocial, and behavioral phenomena, and is, therefore,
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DOI 10.1007/s00415-011-5962-8challenging to deﬁne [4]. However, some deﬁnitive char-
acteristics of PSF have been reported: it is qualitatively
different from the fatigue experienced by patients before
stroke, it is exacerbated by stress and physical exercise, and
it responds well to rest, sleep, and low temperatures—the
last three being rarely described in association with either
chronicfatiguesyndrome (CFS)ordepression[3].Although
fatigue and depression are unquestionably related, fatigue
can reportedly occur in the absence of depression, with one
study ﬁnding that only 38% of patients with severe fatigue
after stroke met the criteria for depression [5].
The best way to treat PSF is uncertain. A recent Coch-
rane study that evaluated different interventions for PSF by
reviewing three trials found that there is currently insufﬁ-
cient evidence to guide the management of fatigue after
stroke [6]. Furthermore, despite the high clinical relevance,
there are few studies on the pathophysiology of PSF. It has
been postulated that fatigue is related to an immune dys-
regulation with cytokine abnormities in CFS [7–10], Par-
kinson’s disease [11], multiple sclerosis [12], ﬁbromyalgia
[13], and cancer [14].
There is considerable evidence that cytokines contribute
to inﬂammation in both the central and peripheral nervous
systems associated with stroke [2, 15, 16]. Several studies
performed in recent decades have examined the relation-
ship between cytokines and outcome in stroke. It has been
found that elevated levels of inﬂammatory markers, and
especially interleukin (IL)-6, are associated with poor
outcomes in stroke [17–21].
We are not aware of previously published data on the
relationship between serum cytokine levels and the severity
of fatigue following stroke. This study investigated whe-
ther serum levels of various cytokines, C-reactive protein
(CRP), hemoglobin and glucose, and stroke lateralization,
subtype, and infarct volume in acute ischemic stroke (AIS)
patients can predict the level of PSF, as measured using the
score on the Fatigue Severity Scale (FSS) at 6, 12, and
18 months after stroke onset.
Subjects and methods
Patients
The cohort comprised 45 patients who were part of a
longitudinal study of ﬁrst-ever stroke patients admitted to
Buskerud Hospital, a regional hospital in Norway. The
recruiting procedure is described in detail elsewhere [22].
In short, the inclusion criteria were clinical presentation of
ﬁrst-ever stroke, age 18 years or older, and exhibiting
sufﬁcient cognitive functioning to participate. Stroke was
deﬁned as the presence of rapidly developing focal neu-
rological signs or symptoms of vascular origin that
persisted for[24 h. The exclusion criteria were no serum
samples collected, uncertain diagnosis of AIS, presence of
cancer, receiving thrombolysis therapy, and uncertain
symptom onset.
Clinical and instrumental evaluation
A general medical history was collected, and physical and
neurological examinations, standard laboratory tests,
12-lead electrocardiogram, and cerebral computed tomog-
raphy (CT) imaging were performed in all patients upon
admission. Patients without clear radiological ﬁndings on
admission but with persistent clinical symptoms indicative
of AIS after 2–4 days submitted to a secondary CT or
magnetic resonance imaging (MRI) scan. The imaging used
for measurement of infarct volume was performed within
1–7 daysafterstroke onset.Thetype ofAISwasdetermined
according to the Trial of Org 10172 in Acute Stroke Treat-
ment (TOAST) classiﬁcation: cardioembolic infarct (CEI),
large-artery atherosclerosis (LAAS), lacunar infarct (LAC),
stroke of undetermined etiology (UDE), and stroke of other
determined etiology [23]. Lateralization of the stroke was
determined by clinical ﬁndings and imaging results, or on a
clinical basis (only in patients without conclusive CT or
MRI ﬁndings). Location of the stroke, supra- or infratento-
rial respectively, was determined by radiologically ﬁndings.
Imaging and volumetric analysis
When possible, infarct volumes were measured on either
MRI (24/34 cases) or CT (10/34 cases). In MRI, diffusion
sequences were used in the axial plane, combined with
sagittal T2 turbo spin-echo and/or coronal ﬂuid-attenuated
inversion recovery imaging, using an on-screen measuring
technique. In CT, measurements were made on axial slices
in combination with thickness data.
Blood collection and serum preparation
Blood samples were taken at \24, 24–48, and 48–72 h
after stroke onset in 35, 7, and 3 of the 45 patients,
respectively, and collected into 7.5-ml serum S-Monovette
gel tubes (Sarstedt, Nu ¨mbrecht, Germany). Samples were
stored for 30–120 min at room temperature prior to cen-
trifugation at 1,4009g for 12 min. Serum samples were
aliquoted at 500 ll into Eppendorf tubes and subjected to
instant freezing at -70C, within 5 h of blood sampling.
CRP, glucose, and hemoglobin measurements
Serum levels of CRP, glucose, and hemoglobin were all
determined using clinically validated assays: a standard
latex immunoassay (CRP Vario, Abbott Diagnostics),
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120 Hematology system (Siemens Health Care Diagnos-
tics), respectively.
Cytokine measurement
Cytokine levels were measured using a Luminex IS 100
instrument (Bio-Rad, Hercules, CA, USA). Based on a
screening of representative serum samples using the Bio-
Plexhumancytokine27-plexassay(catalogno.171A11127,
Bio-Rad), the following custom plex was purchased to
screen all samples: Bio-Plex Pro Human Cytokine Group
I—IL-1b, IL-1ra, IL-2, IL-4, IL-6, IL-8, IL-9, IL-10, IL-12,
tumor necrosis factor (TNF)-a, and interferon-c; Bio-Plex
Pro Human Cytokine Group II; growth-related oncogene
(GRO)-a (CXCL1); and IL-18 (Bio-Rad). All samples were
thawed on ice, vortexed, spun down at 14,0009g for 10 min
at 4C, and then diluted at 1:4. Longitudinal controls were
used to assess the interassay variation. The coefﬁcient of
variation for controls ranged from 9 to 19% on the expo-
nential phase of the standard curve.
Clinical measurements
Barthel Index
Functional disability was measured using the Barthel-20
Index (BI-20) [24] at admission, and then again at 6, 12,
and 18 months thereafter. This index is currently regarded
to be the most reliable disability scale for stroke, and is
highly correlated with the immediate poststroke condition
[25].
FSS score
The FSS, which was used to assess the severity of fatigue
[26], was originally designed to determine the impact of
fatigue in patients with multiple sclerosis [26], but has also
been used frequently to assess stroke patients [27–32]. The
FSS contains nine items, each of which is scored from 1 to
7, with a higher score indicating a greater impact of fatigue
on the patient’s daily life. The sum score is the mean of the
nine items. The FSS has an internal consistency (Cron-
bach’s a) of 0.89 [31]. The aforementioned studies deﬁned
fatigue as being present if the FSS score was above 4 [27–
32], indicating a moderate to high impact of fatigue on
daily living. The distinction between normal and abnormal
fatigue is not clear; linear models treating FSS score as a
continuous variable were thus used in the present study
when analyzing potential associations between variables.
For each of the variables found to be signiﬁcantly associ-
ated with the FSS score (p\0.05), means/medians and
proportions of participants falling into groups based on FSS
scores are presented in Table 2 (those with FFS C 4 and
those with FSS\4).
Statistical analysis
If more than 50% of the values of a particular cytokine
were not detectable, that cytokine was dichotomized as
detectable (yes/no) and analyzed using Pearson’s chi-
square test. Since the distributions of most of the cytokines
were markedly skewed, the results are presented as medi-
ans and interquartile ranges (IQRs).
The independent-samples t-test was used when com-
paring means from the two FSS groups. Skewed contin-
uous variables are presented as median and IQR values,
and the two-tailed Mann–Whitney test was used to
compare the median values of cytokines between the two
FSS groups. The Spearman correlation coefﬁcient was
used to quantify associations between infarct volume and
blood components and BI-20. In addition, in order to be a
confounder for the relation between glucose or a cytokine
variable and later fatigue, the variable must be associated
both with glucose or the cytokine variable and be a pre-
dictor for fatigue.
All statistical analyses were performed using the SPSS
statistical package (version 15).
Results
The study patients comprised 27 males and 18 females
aged between 37 and 85 years (mean age 67.7 ± 11.8
years), of which 22, 21 and 2 had right-, left-sided and
bilateral ischemic stroke, respectively.
TOAST classiﬁcation yielded groups that were too small
to allow for more detailed statistical analysis. We thus
dichotomized the patients into radiologically conﬁrmed
infarctions (merged TOAST criteria for CEI, LAAS, and
LAC; n = 34) and radiologically unconﬁrmed infarctions
(TOAST criteria for UDE; n = 11). Of the 34 patients with
radiologically conﬁrmed stroke, 30 had supratentorial,
while 4 had infratentorial ﬁndings. The stroke volume
measured in the 34 patients with radiologically conﬁrmed
stroke ranged from 0.5 to 140 cm
3 (median, 2 mm
3;I Q R ,
1, 17 mm
3).
The following comorbidities were found: hypertension
(n = 28), atrial ﬁbrillation (n = 6), coronary disease
(n = 7), diabetes (n = 4), rheumatism (n = 2), psoriatic
arthritis (n = 3), Bechterew’s disease (n = 1), and hyper-
thyroidism (n = 1). While 39 patients did not use any
immunosuppressant, 3 were medicated with prednisolone
and 3 with nonsteroidal anti-inﬂammatory drugs.
The percent of patients with BI-20 score equal to 20 was
71.2, 70.5 and 78.6%, at 6, 12 and 18 months, respectively.
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time points were 4.2 ± 1.4, 4.2 ± 1.4 and 4.4 ± 1.4,
respectively.
Associations between various values and FSS scores
measured at 6, 12, and 18 months after stroke are presented
in Table 1; Table 2 lists the signiﬁcant ﬁndings from
Table 1.FSSdataaredichotomizedasFSSscore\4andC4.
The acute serum levels of IL-1b and glucose were
positively correlated with FSS score at 6 months after the
stroke (r = 0.37, p=0.015, and r = 0.37, p=0.017,
respectively). The glucose level was 7.55 ± 2.73 and
6.25 ± 1.35 mmol/l (mean ± SD) in the FSS C 4 and
FSS\4 groups, respectively. Furthermore, IL1-b was
detectable in 32% of the FSS C 4 group and in 13% of the
FSS\4 group. The baseline BI-20 values were negatively
correlated with FSS score at 6 months after the stroke
(r=-0.35, p=0.023).
Acute serum levels of IL-ra and IL-9 were negatively
correlated (r=-0.38, p=0.013, and r=-0.36,
p=0.019, respectively), and those of glucose positively
correlated (r = 0.37, p=0.016) with FSS score at
12 months after the stroke. The FSS C 4 group had a
signiﬁcantly lower median value of IL-1ra [1,021 lg/ml
(IQR, 761–1,364 lg/ml) versus 1,561 lg/ml (IQR, 985–
2,023 lg/ml)] and a lower proportion of patients with
detectable values of IL-9 (29 vs. 61%) than the FSS\4
group. The glucose levels in these two groups were
7.8 ± 2.7 and 6.02 ± 1.1 mmol/l, respectively.
Table 1 Factors associated with FSS score at 6, 12, and 18 months after stroke onset; correlation coefﬁcients and p values (based on the FSS
score as a continuous variable)
Variable FSS score at 6 months FSS score at 12 months FSS score at 18 months
Gender p=0.991 p=0.752 p=0.952
Age, years r=-0.3, p=0.14 r = 0.20, p=0.192 r = 0.26, p=0.102
Radiologically conﬁrmed infarction p=0.311 p=0.048 p=0.123
Yes 4.1 ± 1.4 3.9 ± 1.4 4.2 ± 1.3
No 4.6 ± 1.3 4.9 ± 1.3 4.9 ± 1.5
Infarction side p=0.76 p=0.34 p=0.91
Right (n = 22) 4.3 ± 1.3 4.4 ± 1.4 4.3 ± 1.7
Left (n = 21) 4.2 ± 1.3 4.0 ± 1.3 4.4 ± 1.1
Location ** *
Supratentorial (n = 30) 4.1 ± 1.3 4.0 ± 1.4 4.2 ± 1.2
Infratentorial (n = 4) 4.6 ± 1.7 3.5 ± 1.3 4.1 ± 1.8
Infarct volume (cm
3) r=-0.18, p=0.313 r = 0.15, p=0.405 r = 0.02, p=0.927
BI-20 baseline r=– 0.35, p=0.023 r=-0.18, p=0.263 r=-0.2, p=0.224
Glucose r = 0.37, p=0.017 r = 0.37, p=0.016 r = 0.27, p=0.09
Hemoglobin r = 0.1, p=0.543 r=-0.051, p=0.744 r=-0.21, p=0.175
CRP r = 0.02, p=0.882 r = 0.01, p=0.935 r=-0.7, p=0.664
IL-1ra (lg/ml) r=-0.02, p=0.917 r=20.38, p=0.013 r=-0.28, p=0.077
IL-8 (lg/ml) r=-0.23, p=0.131 r=-0.03, p=0.858 r = 0.12, p=0.452
IL-18 (lg/ml) r=-0.04, p=0.795 r=-0.05, p=0.730 r=-0.28, p=0.072
GRO-a r=-0.09, p=0.551 r=-0.19, p=0.226 r = 0.05, p=0.755
IL-1b r = 0.37, p=0.015 r = 0.09, p=0.571 r=-0.07, p=0.677
IL-2 r = 0.27, p=0.084 r = 0.27, p=0.075 r = 0.19, p=0.222
IL-4 r = 0.09, p=0.556 r=-0.17, p=0.289 r=-0.004, p=0.981
IL-6 r = 0.18, p=0.242 r = 0.1, p=0.514 r = 0.07, p=0.661
IL-9 r = 0.07, p=0.665 r=20.36, p=0.019 r=-0.02, p=0.882
IL-10 r = 0.09, p=0.553 r = 0.1, p=0.535 r=-0.1, p=0.55
IL-12 r = 0.11, p=0.476 r=-0.2, p=0.205 r=-0.1, p=0.549
INF-c r = 0.2, p=0.189 r = 0.05, p=0.763 r = 0.11, p=0.506
TNF-a r = 0.06, p=0.710 r=-0.06, p=0.693 r=-0.09, p=0.594
The independent-samples t-test was used when comparing means from the two FSS groups
The Spearman correlation coefﬁcient was used to quantify associations between infarct volume, blood components and BI-20
Signiﬁcant ﬁndings (p\0.05) are indicated in bold
*Signiﬁcance was not calculated due to small group size (n = 4)
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those with a radiologically conﬁrmed infarction than in
those without such conﬁrmation (p=0.048). Moreover, a
radiologically conﬁrmed infarction was present in 67% of
the FSS C 4 group and 86% of the FSS\4 group.
FSS scores at 18 months after the stroke was not asso-
ciated with any of the variables measured.
Age, gender, hypertension, atrial ﬁbrillation, medica-
tion, coronary disease and baseline BI-20 were not signif-
icant confounders for the signiﬁcant associations between
fatigue at 6 and 12 months and baseline cytokine/glucose
levels.
Discussion
We found that neither stroke lateralization nor infarct
volume were associated with subsequent fatigue. This
ﬁnding is in accordance with those of several other studies
that have evaluated stroke location [27, 33, 34], and vol-
ume [27]. In our study, the group with infratentorial ﬁnd-
ings was too small (n = 4) to allow for detailed statistical
analysis on location. Two other studies found no associa-
tion between TOAST subtype and subsequent fatigue [33,
34]. In our study, TOAST classiﬁcation yielded groups that
were too small to allow a more detailed statistical analysis.
However, after dichotomizing our cohort into those with
radiologically conﬁrmed infarctions and those without, we
found that the latter had signiﬁcantly higher FSS scores at
12 months after stroke onset (p=0.048). We have previ-
ously found that patients with radiologically conﬁrmed
infarctions were signiﬁcantly younger and had signiﬁcantly
higher serum levels of GRO-a than those without such
conﬁrmation [35]. However, FSS scores at 12 months were
not correlated with either age or GRO-a. Thus, the differ-
ence in FSS scores between these two groups cannot be
explained by differences in age or GRO-a.
Our ﬁnding of more severe fatigue observed among
patients with UDE (cryptogenic stroke) is interesting. We
did not identify a biological origin for this ﬁnding, and it is
possible that this phenomenon is of a more psychosocial
nature. For example, the diagnosis of ‘‘unconﬁrmed’’
stroke may confer a lack of acknowledgment upon patients,
generating within them a feeling of uncertainty and spec-
ulation. More research is needed to investigate this possi-
bility, moving into the interesting ﬁeld of the biological
versus psychosocial aspects of PSF.
We found signiﬁcantly higher acute levels of IL-b and
glucose in stroke patients with more severe fatigue at
6 months after stroke. Signiﬁcantly higher levels of glu-
cose and lower levels of IL1-ra and IL-9 were found in
patients with more severe fatigue at 12 months after stroke.
These ﬁndings indicate that high levels of glucose and IL-
1b and low levels of IL-1ra and IL-9 in the acute phase of
AIS may predict subsequent fatigue, indicating that the
proinﬂammatory response in AIS may be responsible for
the development of PSF.
Our ﬁnding that IL-1b is a predictor of PSF may be
explained by the concept of cytokine-induced sickness
behavior, whereby sickness behavior is induced by physi-
ological concentrations of proinﬂammatory cytokines act-
ing in the brain after infection, the symptoms being loss of
appetite, sleepiness, withdrawal from normal social activ-
ities, fever, aching joints, and fatigue [36]. IL-1b is one of
the two main proinﬂammatory cytokines involved in
sickness behavior, the other being TNF-a [37]. The most
plausible mechanism by which proinﬂammatory cytokines
could induce mental fatigue is disturbance of glutamate
signaling, which is crucial for information gathering and
processing within the brain. The hypothesis is that proin-
ﬂammatory cytokines TNF-a, IL-1b, and IL-6 act in the
pathophysiology of mental fatigue via their ability to
attenuate the astroglial clearance of extracellular gluta-
mate, their disintegration of the blood–brain barrier, and
their effects on astroglial metabolism and the neuronal
metabolic supply, thereby attenuating glutamate transmis-
sion [38].
IL1-ra, the naturally occurring antagonist of IL-1b,i s
known to be neuroprotective [39], and, relevant to the
focus of our study, attenuates sickness behavior in
Table 2 Signiﬁcant ﬁndings from Table 1; data presented for FSS score dichotomized as\4 and C4
Variable At 6 months At 12 months
FSS score\4 FSS score C4 FSS score\4 FSS score C4
Radiologically conﬁrmed infarction,
dichotomized values [n yes (% of total)]
– – 17 (86%) 16 (67%)
Glucose, mmol/l, mean ± SD 6.25 ± 1.35 7.55 ± 2.73 6.02 ± 1.1 7.8 ± 2.7
BI-20 at baseline, mean ± SD 20 ± 0.9 18±3.2 – –
IL-1ra, lg/ml, median (IQR) – – 1561 (985–2,023) 1021 (761–1,364)
IL-1b, lg/ml, dichotomized values [n detectable (% of total)] 1 (13%) 9 (32%) – –
IL-9, lg/ml, dichotomized values [n detectable (% of total)] – – 11 (61%) 7 (29%)
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interaction or food intake) [40]. Furthermore, Emsley and
coworkers [41] identiﬁed recombinant human IL-1ra (rhIL-
1ra) as a potential new therapeutic agent for acute stroke,
after they found that clinical outcomes at 3 months among
patients with cortical infarcts were better in the rhIL-1ra-
treated group than in the placebo-treated group. To the best
of our knowledge, our ﬁnding that IL-ra is negatively cor-
related with the severity of PSF is novel and also supports
the previous ﬁndings and approaches discussed above.
Elevated blood glucose is common in the early phase of
stroke; hyperglycemia (blood glucose level [6.0 mmol/l)
has been observed in two-thirds of all ischemic stroke
subtypes on admission [42]; in our study, 60% of the
patients had blood glucose levels[6.0 mmol/l. High levels
of glucose were found to predict fatigue after 6 and
12 months. Hyperglycemia is associated with impaired
clinical outcome [43–45], and signiﬁcantly worsens both
cortical intracellular brain acidosis and mitochondrial
function in the ischemic penumbra, which supports the
hypothesis that the evolution of acidosis in the ischemic
penumbra is related to glucose utilization [46]. Hypergly-
cemia most probably effects direct membrane lipid per-
oxidation and cell lysis in metabolically challenged tissue
by provoking anaerobic metabolism, lactic acidosis, and
free-radical production [47]. We have found no previous
data on the relationship between hyperglycemia and PSF,
or any other type of illness-related fatigue, and thus believe
these ﬁndings to be novel.
The role of IL-9 in AIS remains unclear, although we
have previously found a signiﬁcant elevation of serum IL-9
levels in AIS patients (unpublished results). We, therefore,
believe that we are the ﬁrst to show that IL-9 is negatively
correlated with FSS at 6 months after stroke onset. It has
been shown that the IL-9/IL-9 receptor signaling pathway
represents a novel endogenous anti-apoptotic mechanism
for cortical neurons [48]. We therefore speculate that IL-9
protects against stress-induced neuronal damage. Further
research on the role of IL-9 in AIS is required.
The relationships between cytokines and fatigue found
at 6 and 12 months disappeared after 18 months. The fact
that the mean fatigue score had not declined at this time
point, leads us to speculate that other, most probably psy-
chosocial, factors have contributed to the sustained level of
fatigue this late after stroke. Qualitative research of post
stroke fatigue indicates that lack of information and
knowledge about the fatigue problem following stroke,
which may generate a feeling of lack of acknowledgment,
leads to additional distress for the patients [49–51]. We
hypothesize that this may be a contributing factor for the
prolonging of fatigue post stroke.
Considering the relatively high number of signiﬁcant
tests performed in our study, the possibility of at least one
false signiﬁcant result is relatively high. This should be
taken into account when interpreting the results.
Conclusion
To the best of our knowledge, this is the ﬁrst analysis of
cytokines and glucose as possible predictors of fatigue
following AIS. Thus, our study should be regarded pri-
marily as a hypothesis-generating one (i.e., the ﬁndings
must be veriﬁed in future studies before being interpreted
as valid). Our study supports the notion that PSF may be
attributable to cytokine activation, most probably by dis-
turbing glutamate signaling. Our ﬁndings regarding IL1-b
and IL-1ra support this theory.
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